Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study. by DeFilipp, Zachariah et al.
 
Journal Pre-proof
Maintenance tyrosine kinase inhibitors following allo-HCT for chronic
myeloid leukemia: A CIBMTR Study
Zachariah DeFilipp , Richard Ancheta , Ying Liu , Zhen-Huan Hu ,
Robert Peter Gale , David Snyder , Harry C. Schouten ,
Matt Kalaycio , Gerhard C. Hildebrandt , Celalettin Ustun ,
Andrew Daly , Siddhartha Ganguly , Yoshihiro Inamoto ,
Mark Litzow , Jeffrey Szer , Mary Lynn Savoie , Nasheed Hossain ,
Mohamed A. Kharfan-Dabaja , Mehdi Hamadani , Ran Reshef ,
Ashish Bajel , Kirk R. Schultz , Shahinaz Gadalla , Aaron Gerds ,
Jane Liesveld , Mark B. Juckett , Rammurti Kamble ,
Shahrukh Hashmi , Hisham Abdel-Azim , Melhem Solh ,
Ulrike Bacher , Hillard Lazarus , Richard Olsson ,
Jean-Yves Cahn , Michael R. Grunwald , Bipin N. Savani ,
Jean Yared , Jacob M. Rowe , Jan Cerny , Naeem A. Chaudhri ,
Mahmoud Aljurf , Amer Beitinjaneh , Sachiko Seo ,
Taiga Nishihori , Jack W. Hsu , Muthalagu Ramanathan ,
Edwin Alyea , Uday Popat , Ronald Sobecks , Wael Saber
PII: S1083-8791(19)30674-3
DOI: https://doi.org/10.1016/j.bbmt.2019.10.017
Reference: YBBMT 55765
To appear in: Biology of Blood and Marrow Transplantation
Received date: 18 July 2019
Accepted date: 16 October 2019
Please cite this article as: Zachariah DeFilipp , Richard Ancheta , Ying Liu , Zhen-Huan Hu ,
Robert Peter Gale , David Snyder , Harry C. Schouten , Matt Kalaycio , Gerhard C. Hildebrandt ,
Celalettin Ustun , Andrew Daly , Siddhartha Ganguly , Yoshihiro Inamoto , Mark Litzow ,
Jeffrey Szer , Mary Lynn Savoie , Nasheed Hossain , Mohamed A. Kharfan-Dabaja ,
Mehdi Hamadani , Ran Reshef , Ashish Bajel , Kirk R. Schultz , Shahinaz Gadalla ,
Aaron Gerds , Jane Liesveld , Mark B. Juckett , Rammurti Kamble , Shahrukh Hashmi ,
Hisham Abdel-Azim , Melhem Solh , Ulrike Bacher , Hillard Lazarus , Richard Olsson ,
Jean-Yves Cahn , Michael R. Grunwald , Bipin N. Savani , Jean Yared , Jacob M. Rowe ,
Jan Cerny , Naeem A. Chaudhri , Mahmoud Aljurf , Amer Beitinjaneh , Sachiko Seo ,
Taiga Nishihori , Jack W. Hsu , Muthalagu Ramanathan , Edwin Alyea , Uday Popat ,
Ronald Sobecks , Wael Saber , Maintenance tyrosine kinase inhibitors following allo-HCT for
chronic myeloid leukemia: A CIBMTR Study, Biology of Blood and Marrow Transplantation (2019), doi:
https://doi.org/10.1016/j.bbmt.2019.10.017
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
4
7
0
4
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2019 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular
Therapy
Highlights 
 Maintenance TKI therapy did not significantly impact allo-HCT outcomes for 
CML.  
 Results were not modified by the status of disease prior to transplant. 
 The optimal approach to TKI therapy after allo-HCT remains undetermined. 
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Abstract 
It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) 
targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is 
associated with improved outcomes for patients with chronic myeloid leukemia (CML). 
In this registry study, we analyzed clinical outcomes of 390 adult patients with CML 
         
transplanted from 2007-2014 who received maintenance TKI following HCT (n=89) as 
compared to no TKI maintenance (n=301), as reported to the Center for International 
Blood and Marrow Transplant Research. All patients received TKI therapy prior to HCT. 
The majority of patients had disease beyond CP1 at HCT (n=240, 62%). The study was 
conducted as a landmark analysis, excluding patients that died, relapsed, had chronic 
graft-versus-host disease or were censored prior to Day 100 following HCT. Of the 89 
patients receiving TKI maintenance, 77 (87%) received a single TKI while 12 (13%) 
received multiple sequential TKIs. The most common TKIs used for maintenance were 
dasatinib (n=50), imatinib (n=27) and nilotinib (n=27). As measured from Day 100, the 
adjusted estimates for 5-year relapse (maintenance, 35% vs. no maintenance, 26%; 
p=0.11), leukemia-free survival (LFS, maintenance, 42% vs. no maintenance, 44%; 
p=0.65) or overall survival (OS, maintenance, 61% vs. no maintenance, 57%; p=0.61) 
did not significantly differ between patients receiving TKI maintenance or no 
maintenance. These results remained unchanged in multivariate analysis and were not 
modified by the status of disease prior to transplant. In conclusion, our data did not 
demonstrate a significant impact of maintenance TKI therapy on clinical outcomes in a 
Day 100 landmark analysis. The optimal approach to TKI administration in the post-
transplant setting in CML remains undetermined. 
 
Keywords: chronic myeloid leukemia; tyrosine kinase inhibitor; allogeneic 
hematopoietic cell transplantation; maintenance; 
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Introduction 
The introduction of tyrosine kinase inhibitors (TKIs) that target BCR-ABL1 changed the 
therapeutic landscape for chronic myeloid leukemia (CML) and significantly improved 
clinical outcomes, with long term overall survival (OS) increasing from <20% to 80-
90%.1, 2 Allogeneic hematopoietic cell transplantation (HCT) remains the only known 
curative treatment for CML. However, given the success of TKIs and the risks 
associated with transplant, HCT is currently reserved for patients with accelerated (AP) 
and blast phase (BP) CML and for TKI failure or intolerance in chronic phase (CP) 
disease.3 Despite the addition of TKIs prior to HCT, outcomes of patients receiving 
transplant have not significantly changed, with disease relapse being the leading cause 
of HCT failure.4, 5  
 
Maintenance therapy, defined as therapy initiated while the patient remains in complete 
remission, is a promising approach to reduce the incidence of relapse after HCT.6 The 
administration of TKIs as maintenance after allogeneic HCT for patients with high-risk 
Philadelphia chromosome-positive (Ph+) leukemia has been investigated in select 
studies7-10 and this approach is already being adopted into clinical practice.11 While the 
use of maintenance TKI after HCT was associated with improved leukemia-free survival 
(LFS) and OS for patients with Ph+ acute lymphoblastic leukemia in an analysis from 
the European Group for Blood and Marrow Transplantation (EBMT)12, larger studies 
investigating maintenance approaches in CML are lacking. Given the changing role of 
         
HCT in the management of CML and the increasing utilization of TKIs in the post-
transplant period, we sought to determine whether maintenance therapy with TKIs 
following HCT is associated with improved disease control and survival for patients with 
CML through analysis of the Center for International Blood and Marrow Research 
(CIBMTR) registry. We additionally sought to characterize the utilization and outcomes 
of HCT in the management of CML in a modern era of multiple available TKIs.   
 
Methods 
Data Sources 
The CIBMTR is a combined research program of the Medical College of Wisconsin and 
the National Marrow Donor Program, which consists of a voluntary network of more 
than 450 transplantation centers worldwide that contribute detailed data on consecutive 
allogeneic and autologous transplantations to a centralized statistical center. 
Observational studies conducted by the CIBMTR are performed in compliance with all 
applicable federal regulations pertaining to the protection of human research 
participants. Protected health information issued in the performance of such research is 
collected and maintained in the CIBMTR’s capacity as a Public Health Authority under 
the Health Insurance Portability and Accountability Act Privacy Rule.  
 
The CIBMTR collects data, which include the following: age, sex, disease type, pre-
transplant disease stage, date of diagnosis, graft type, conditioning regimen, post-
transplant disease progression and survival, development of a new malignancy, and 
cause of death. Data are collected before transplantation, 100 days and 6 months after 
         
transplantation, and annually thereafter or until death. The study protocol received a 
priori approval by the appropriate institutional review committee.  
 
Study Population 
The study population identified with the CIBMTR database included patients who 
underwent allogeneic HCT between 2007 and 2014. Patients identified were 18 years of 
age or older and underwent allogeneic HCT for CML for the first time. Donors were 
HLA-identical sibling donors, unrelated donors (URD), or umbilical cord blood. Patients 
who had not received TKIs prior to HCT and patients receiving therapies other than 
TKIs as maintenance following HCT were excluded. Patients who received ex-vivo T-
cell depletion, CD34 selection, or post-transplant cyclophosphamide as graft-versus-
host disease (GVHD) prophylaxis were also excluded. Published experiences with 
maintenance TKIs have reported a median initiation date between Day 30 and Day 100 
following allogeneic HCT.7-11 Thus, we chose to conduct this study as a landmark 
analysis that excluded patients that died, relapsed, had cGVHD or were lost to follow up 
prior to Day 100 post-HCT.  
 
Variables Included in the Analysis 
The data analysis included patient-related variables were the age at HCT, sex, and 
Karnofsky performance status (KPS). Disease-related variables included the disease 
status at transplant (CP1 vs. CP2+ vs. AP vs. BP). Transplant-related variables included 
conditioning regimen intensity (as defined by the CIBMTR),13 donor-recipient HLA-
match (HLA-identical sibling, well matched URD, partially matched URD, mismatched 
         
URD),14 GVHD prophylaxis, and the time period in which the transplant was performed 
(2007-2008, 2009-2010, 2011-2012, 2013-2014). Maintenance therapy was determined 
based on data recorded from the Day 100 post-HCT disease specific form, which 
included the choice of TKI but not the date of initiation, dose or the duration of 
maintenance therapy. Relapse was defined by report of molecular, cytogenetic, and/or 
hematologic disease post-HCT. 
 
Study Endpoints and Statistical Analysis 
This was a retrospective cohort landmark study from 100 days after HCT to compare 
outcomes of patients transplanted with CML who received maintenance TKI therapy to 
controls (no maintenance therapy). The primary aim was to compare LFS, and the 
secondary aim was to compare the OS, chronic GVHD, TRM and relapse between 
these 2 groups. All the outcomes are time to events with the starting time at 100 days 
after transplantation.  
 
Descriptive statistics were calculated for all variables. A univariate analysis was 
performed with the Kaplan-Meier estimates to compute OS and LFS rates. Log-rank 
tests were used to measure the differences of OS and LFS between the treatment 
groups. Chronic GVHD, TRM and relapse rates were estimated with the cumulative 
incidence functions with consideration of competing risks. Gray’s test was performed to 
compare the differences of cumulative incidence functions between treatment groups. 
 
         
Multivariate Cox proportional hazards regression models for all the endpoints (LFS, OS, 
relapse TRM, and cGVHD) were used to compare the treatment groups. The 
assumption of proportional hazards for each factor in the Cox model was tested using 
time-dependent covariates. There is no variable violating the proportional hazard 
assumption in this study. Stepwise selection was used to identify significant covariates 
that influenced outcomes to be included in the final model to get the adjusted treatment 
effects. The set of adjusting variables for each outcome was decided separately by 
stepwise selection with inclusion criteria at 0.05. Statistical significance of the main 
effects was tested with level 0.01 accounting for multiple comparisons across the 
endpoints. Potential interactions between the main effect and significant adjusting 
covariates and between main effect and donor type were tested and there are no 
significant interactions at level of 0.01. 
 
Adjusted survival curves and cumulative incidence curves were generated stratified on 
the treatment groups and weighted averages of covariate values using the pooled 
sample proportion as the weight function. These adjusted curves represent likelihood of 
outcomes in populations with similar prognostic factors. 
 
Results 
Patient and Transplant Characteristics 
In total, 572 patients with CML were initially identified according the defined study 
population (Supplemental Tables 1a and 1b). Of this, 182 patients were excluded as 
part of the Day 100 landmark criteria (Figure 1, Supplemental Table 2), leaving 390 
         
eligible patients for the analysis. Two cohorts were identified: 1) those receiving post-
HCT maintenance TKI therapy (n=89), and 2) those not receiving post-HCT 
maintenance TKI therapy (n=301). Patient characteristics are outlined in Table 1. The 
median follow-up for survivors after Day 100 post-HCT was 61 months (range, 7-97) in 
the maintenance TKI cohort and 68 months (range, 2-98) in the no maintenance cohort. 
There was no difference in median age, sex, or KPS at HCT between the two groups. 
Overall, the majority of patients had disease beyond CP1 at HCT (n=240, 62%). 
Disease status prior to HCT differed between the two groups, with a higher percentage 
of patients CP2+ being in the maintenance cohort and a higher percentage of patients 
with CP1 in the no maintenance cohort (p<0.001). Transplant characteristics were 
similar between the two cohorts in regards to the most common donor types (HLA 
matched siblings and unrelated donors), graft source (peripheral blood stem cells), 
conditioning intensity (myeloablative) and GVHD prophylaxis (calcineurin inhibitor plus 
methotrexate). The administration of donor lymphocyte infusions as prophylaxis or for 
mixed chimerism was rare (TKI maintenance, n=0; no TKI maintenance, n=4).  
 
TKI therapy prior to HCT 
All patients in this analysis received TKI therapy prior to transplant, with the majority of 
patient receiving multiple TKIs in both the maintenance (67%) and non-maintenance 
cohorts (75%). The most commonly used TKIs prior to HCT were imatinib (n=362), 
dasatinib (n=276), and then nilotinib (n=125). The duration of TKI therapy prior to HCT, 
as well as the reason for multiple TKI use (resistance, intolerance or other), were 
unavailable.  
         
 
Maintenance TKI therapy after HCT 
Eighty-nine patients (23%) received TKI maintenance therapy after HCT (Table 2). Of 
these, 77 (87%) received a single TKI and 12 (13%) received multiple TKIs. In the 
majority of cases (n=72, 81%), a different TKI was administered post-HCT as compared 
to pre-HCT. The most common TKIs used for maintenance were dasatinib (n=50), 
imatinib (n=27), and nilotinib (n=27). The start date and duration of maintenance TKI 
therapy were unavailable.  
 
OS  
We observed no significant difference in the adjusted 2-year and 5-year OS from Day 
100 between the two cohorts (2-year: 76% (95% confidence interval [CI], 68-85%) for 
the maintenance cohort, 69% (95% CI, 64-82%) for the no maintenance cohort 
(p=0.15); 5-year: 61% (95% CI, 50-72%) for the maintenance cohort, 57% (95% CI, 52-
67%) for the no maintenance cohort (p=0.61)) (Figure 2). The leading cause of death in 
the maintenance cohort was disease relapse, while the leading cause of death in the no 
maintenance cohort was GVHD (Supplemental Table 3). In the multivariate analysis 
(Table 3), BP disease status prior to HCT, CP2+ disease status prior to HCT, cord 
blood graft source, and peripheral blood graft source were independent adverse risk 
factors for OS (hazard ratio [HR] for BP, 2.4 (reference, CP1): 95% CI, 1.3-4.3, p=0.005; 
HR for CP2+, 1.6 (reference, CP1): 95% CI, 1.1-2.4, p=0.013; HR for cord blood, 2.6 
(reference, bone marrow): 95% CI, 1.4-4.7, p=0.002; HR for peripheral blood, 2.1 
(reference, bone marrow): 95% CI, 1.3-3.4, p=0.004). Maintenance TKI therapy was not 
         
a risk factor for OS (HR 0.7 (reference, no maintenance): 95% CI, 0.5-1.1, p=0.078).  
 
LFS 
We observed no significant difference in the adjusted 2-year and 5-year LFS from Day 
100 between the two cohorts (2-year: 56% (95% CI, 45-66%) for the maintenance 
cohort, 56% (95% CI, 50-61%) for the no maintenance cohort (p=0.95); 5-year: 42% 
(95% CI, 31-53%) for the maintenance cohort, 44% (95% CI, 39-47%) for the no 
maintenance cohort (p=0.65) (Figure 3). In the multivariate analysis (Table 3), BP 
disease status prior to HCT, CP2+ disease status prior to HCT, and age ≥60 were 
independent adverse risk factors for LFS (HR for BP, 1.8 (reference, CP1): 95% CI, 1.0-
3.1, p=0.039; HR for CP2+, 1.7 (reference, CP1): 95% CI, 1.2-2.4, p=0.003; HR for age 
≥60, 2.3 (reference, age 18-29): 95% CI, 1.3-3.9, p=0.004). Maintenance TKI therapy 
was not a risk factor for LFS (HR 0.9 (reference, no maintenance): 95% CI, 0.6-1.2, 
p=0.356). 
 
Relapse 
The most common presentation of relapsed disease in both cohorts were hematologic 
relapses (TKI maintenance, n=22, 69%; no TKI maintenance, n=50, 68%). We observed 
an increased adjusted incidence of relapse at 2-years from Day 100 when comparing 
the TKI maintenance cohort to the no maintenance cohort (2-year: 33% (95% CI, 23-
43%) vs. 22% (95% CI, 17-38%), p=0.04). However, no significant difference was 
observed in 5-year outcomes (35% (95% CI, 25-45%) for the maintenance cohort, 26% 
(95% CI, 21-40%) for the no maintenance cohort (p=0.11)) (Figure 4). In the 
         
multivariate analysis (Table 3), KPS <90 was an independent adverse risk factors for 
relapse (HR for KPS <90, 2.0 (reference, KPS 90-100); 95% CI, 1.3-3.0, p=0.001). 
Maintenance TKI therapy was not a risk factor for relapse (HR 1.4 (reference, no 
maintenance); 95% CI, 0.9-2.1, p=0.170). 
 
TRM 
We observed a lower adjusted incidence of TRM at 1-year from Day 100 when 
comparing the TKI maintenance cohort to the no maintenance cohort (1-year: 8% (95% 
CI, 2-13%) vs. 19% (95% CI, 14-12%) p=0.004). However, no significant difference was 
observed in 5-year outcomes (23% (95% CI, 13-32%) for the maintenance cohort, 30% 
(95% CI, 25-28%) for the no maintenance cohort (p=0.19)). In the multivariate analysis 
(Table 3), cord blood graft source and peripheral blood graft source were independent 
adverse risk factors for TRM (HR for cord blood, 2.7 (reference, bone marrow); 95% CI, 
1.2-5.8, p=0.012; HR for peripheral blood, 2.4 (reference, bone marrow); 95% CI, 1.3-
4.4, p=0.006). Maintenance TKI therapy was not a risk factor for TRM (HR 0.7 
(reference, no maintenance); 95% CI, 0.4-1.1, p=0.130). 
 
Chronic GVHD 
We observed no significant difference in the adjusted 2-year cGVHD from Day 100 
between the two cohorts (60% (95% CI, 50-69%) for the maintenance cohort, 62% 
(95% CI, 57-65%) for the no maintenance cohort (p=0.67)). In the multivariate analysis 
(Table 3), peripheral blood graft source was an adverse risk factor for cGVHD (HR for 
peripheral blood, 2.0 (reference, bone marrow); 95% CI, 1.4-2.8, p<0.001) and 
         
cyclosporine based GVHD prophylaxis and KPS <90 were independent protective 
factors against cGVHD (HR for cyclosporine based GVHD prophylaxis, 0.6 (reference, 
tacrolimus based GVHD prophylaxis); 95% CI, 0.4-0.8, p=0.003; HR for KPS <90, 0.6 
(reference, KPS 90-100); 95% CI, 0.4-0.8, p<0.001). Maintenance TKI therapy was not 
a risk factor for cGVHD (HR 0.8 (reference, no maintenance); 95% CI, 0.6-1.1, 
p=0.124). 
 
Subgroup analysis investigating disease status prior to HCT 
We specifically investigated the interaction of the main effect (TKI maintenance or no 
maintenance) on the primary outcomes of the study (LFS), according to disease status 
prior to HCT. We observed no differential impact of maintenance TKI on LFS (as 
measured from Day 100 post HCT) based on disease status prior to HCT (Figure 5). 
 
We additionally performed a sensitivity analysis, repeating the above multivariate 
analysis after removing patients with CP1 disease. We observed no differential impact 
of maintenance TKI on major clinical outcomes (OS, LFS, relapse, TRM, chronic 
GVHD) when analyzing patients with disease beyond CP1 at HCT (Supplemental 
Table 4). 
 
Discussion 
In this retrospective registry analysis, we sought to investigate the practice of TKI 
maintenance therapy following HCT in patients with CML. Our results confirm that in a 
modern era of TKI therapy, HCT remains a curative option for patients with CML, with 
         
encouraging survival. We report that the maintenance approach has not been 
universally adopted, as only 23% of patients received TKI maintenance in this data set. 
In a landmark analysis from Day 100, we did not demonstrate a benefit in 5-year clinical 
outcomes (LFS, OS, relapse, TRM or cGVHD) with the use TKI maintenance as 
compared to no maintenance. While TKI maintenance was associated with a higher 
incidence of relapse and lower incidence of TRM at earlier time points as compared to 
the no maintenance cohort, these findings did not maintain significance when analyzing 
5-year outcomes or when evaluating the impact of maintenance therapy in the 
multivariate Cox proportional hazards regression model. The results of this study 
characterize the clinical outcomes of patients receiving TKI maintenance and question 
the broad application of this approach to all patients with CML. The impact of 
maintenance TKI did not differ based on disease status prior to HCT, although we 
acknowledge that additional differences in disease risk, as well as physician intent to 
initiate maintenance therapy, could not be accounted for with this registry analysis. 
Nevertheless, we believe the results of this study to be important to clinical practice, 
given the potential toxicities and costs associated with maintenance therapy.  
 
We believe that a number of important factors influenced the outcomes of this study. 
First, we used a landmark analysis from Day 100 following HCT to calculate all follow up 
and outcomes. Evaluation of maintenance therapies is often associated with inherent 
selection bias, as patients must be alive and usually without early major HCT 
complications (relapse, GVHD, infection, organ toxicity), which can confound clinical 
perception of the clinical impact of maintenance approaches. By conducting a landmark 
         
analysis, we excluded patients with early death, relapse, and chronic GVHD, and 
hereby we tried to correct for this bias. However, we postulate that this study design 
may have also influenced the findings at earlier time points of higher relapse and less 
TRM with TKI maintenance, as an increased number of relapses and deaths prior to 
Day 100 were excluded from the no maintenance cohort. Another major factor to 
consider is the heterogeneity in disease risk and its influence on clinician decision to 
initiate TKI maintenance. While we observed differences in disease status prior to 
transplant, we lack additional data on disease risk and TKI sensitivity (including ABL1 
domain mutations). We also do not know the reason for the initiation of TKI 
maintenance or whether patients in the no maintenance cohort were originally intended 
to receive maintenance. While we observed no significant impact of TKI maintenance 
on clinical outcomes in this study, we acknowledge that unmeasured cofounders exist 
that could potentially influence the outcomes of this study. Finally, the majority of 
patients in this study received myeloablative conditioning, which has been associated 
with lower rates of relapse early after HCT when compared with reduced intensity 
conditioning.15 This conditioning intensity may have influenced clinician decision to 
initiate post-HCT maintenance therapy. Given the higher risk for relapse early after HCT 
with RIC, this may be a population in which TKI maintenance may be of more 
importance until the full potency of GVL is in effect. 
 
A small number of studies have investigated the use of prophylactic post-transplant 
maintenance TKIs in patients with Ph+ leukemia. Two early prospective trial of imatinib 
maintenance in the first year following allogeneic HCT found this approach to be 
         
feasible and associated with low rates of relapse.7, 8 As many patients undergoing 
allogeneic HCT have failed first-line TKIs, there is great interest in the post-HCT use of 
later generation TKIs. However, the later generation TKIs in particular have been 
associated with increased toxicities. A phase I/II study investigating nilotinib after 
allogeneic HCT in 16 patients with high-risk Ph+ leukemia reported 2-year OS and 
progression-free survival of 69% and 56%, respectively.9 In this study, 38% of patients 
had to discontinue therapy because of toxicities, which were predominantly 
gastrointestinal or hepatic. In a separate phase I/II study, only 32.5% of patients eligible 
for nilotinib maintenance at engraftment were able to complete the intended 1 year of 
therapy because of early relapse, toxicities or confounding post-HCT complications.10 
Toxicities can limit duration of TKI maintenance, which is thought to impact the 
effectiveness of this approach although no studies to date have addressed a minimum 
or optimal duration of maintenance therapy. No previous registry studies have 
investigated maintenance TKI use in CML, but in an EBMT analysis of Philadelphia 
chromosome-positive acute lymphoblastic leukemia, the use of maintenance TKI post-
transplant was identified to be a significant factor for improved LFS (HR=0.44, P=0.002) 
and OS (HR=0.42, P=0.004) and lower relapse incidence (HR=0.40, P=0.01).12 Patients 
with CML undergoing allogeneic HCT may have increased heterogeneity in disease risk 
and TKI sensitivity (possibly driven by additional mutations outside of BCR-ABL1), 
which may have limit the extent to which registry analyses are able to detect an impact 
of TKI maintenance in CML as compared to Ph+ ALL.  
 
         
The current study has additional limitations. A significant limitation was the relatively 
small size of the cohort of TKI maintenance, although given the current indications for 
HCT in CML, our study represents a comprehensive study cohort. Given the limits of the 
data collected in regards to TKI maintenance, we lack information on the start date, the 
dose, the duration of therapy, and the reason for which TKI maintenance was stopped. 
We acknowledge these limitations restrict our ability to assess the impact of this 
approach, as TKI maintenance therapy may be discontinued after short periods of time 
due to TKI intolerance or other transplant complications.11 As a result, we analyzed 
clinical outcomes according to the initiation of maintenance TKI therapy, as reported to 
the CIBMTR registry, and acknowledge that additional data about maintenance therapy 
could provide insights into its clinical impact. We also lack data in regards to financial 
burden of maintenance therapy and as well as late effects, two important factors that 
can impact quality of life for patients. Finally, this study captures transplants performed 
during an era of expanding TKI agents. Thus, patients in the earlier years of the study 
with resistance or intolerance to imatinib or dasatinib prior to HCT may not have had 
appropriate TKIs with which to continue maintenance. Currently, with five available TKIs 
targeting BCR-ABL1, there is no clear optimal choice of TKI following HCT. 
 
In conclusion, the broad application of maintenance TKI following allogeneic HCT does 
not seem to be of benefit for patients with CML. It remains unclear if there are 
subpopulations of patients with CML who may benefit from TKI maintenance. We 
believe that the choice to initiate TKIs after allogeneic HCT should be an individualized 
decision, based upon patient-, disease-, and transplant-related factors. 
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Figure Legend 
Figure 1. Study flow diagram.  
 
 
 
Figure 2. Kaplan-Meier curve of overall survival according to post-HCT maintenance 
therapy with tyrosine kinase inhibitors. 
 
         
Figure 3. Kaplan-Meier curve of leukemia-free survival according to post-HCT 
maintenance therapy with tyrosine kinase inhibitors. 
 
 
 
Figure 4. Cumulative incidence curve of relapse according to post-HCT maintenance 
therapy with tyrosine kinase inhibitors. 
 
 
 
 
 
         
Figure 5. Forest plot of leukemia free survival according to disease status prior to HCT.   
 
 
 
 
Table 1. Patient, disease, and transplant characteristics. 
 
Variable Post-HCT 
maintenance 
TKI 
No post-HCT 
maintenance 
TKI 
p-value 
Number of patients 89 301  
Number of centers 45 101  
Age, median (range), y 46 (19-64) 44 (18-76) 0.59 
Sex, n (%)   0.23 
   Male 56 (63) 168 (56)  
   Female 33 (37) 133 (44)  
KPS at HCT, n (%)   0.91 
   ≥90 64 (72) 218 (72)  
   <90 23 (26) 74 (25)  
   Missing 2(2) 9(3)  
Number of TKI therapies prior to HCT, n 
(%) 
   
   1 29 (33) 76 (25)  
   >1 60 (67) 225 (75)  
TKI therapies prior to HCT, n (%)    
  Imatinib 77 (87) 285 (94)  
  Dasatinib 63 (71) 213 (71)  
  Nilotinib 25 (28) 100 (33)  
  Ponatinib 0 1 (<1)  
Disease status prior to HCT, n (%)   <0.001 
   CP1 13 (15) 137 (46)  
   CP2+ 53 (60) 95 (32)  
   AP 12 (13) 48 (16)  
   BP 9 (10) 14 (5)  
   Missing 2 (2) 7 (2)  
Graft source   0.69 
         
   Bone marrow 16 (18) 66 (22)  
   Peripheral blood 62 (70) 196 (65)  
   Cord blood 11 (12) 39 (13)  
Donor type, n (%)   0.42 
   HLA-identical sibling 31 (35) 96 (32)  
   Well matched URD 32 (36) 130 (43)  
   Partially matched URD 15 (17) 33 (11)  
   Mismatched URD 0 3 (<1)  
   Cord blood 11 (12) 39 (13)  
Conditioning regimen intensity, n (%)   0.51 
   MAC 76 (85) 250 (83)  
   RIC 8 (9) 40 (13)  
   NMA 5 (6) 10 (3)  
   Missing 0 1 (<1)  
GVHD prophylaxis, n (%)   0.65 
   CNI + MTX 61 (69) 182 (60)  
   CNI + MMF 23 (26) 80 (26)  
   Other 5 (6) 39 (13)  
Year of HCT, n (%)   0.01 
   2007-2008 19 (21) 120 (40)  
   2009-2010 45 (51) 112 (37)  
   2011-2012 9 (10) 22 (7)  
   2013-2014 16 (18) 47 (16)  
Median follow up of survivors after Day 
100 post-HCT (range), m 
61 (7-97) 68 (2-98)  
 
Abbreviations: 
AP: accelerated phase; BP: blast phase; CNI: calcineurin inhibitor; CP: chronic phase; 
CR: complete remission; HCT: hematopoietic cell transplantation; KPS: Karnofsky 
performance status; m: months; MAC: myeloablative conditioning; MMF: mycofenolate 
mofetil; MTX: methotrexate; n: number; NMA: non-myeloablative conditioning; RIC: 
reduced intensity conditioning; TKI: tyrosine kinase inhibitor; URD: unrelated donor; y: 
year; 
 
 
 
 
 
Table 2. Characteristics of post-transplant TKI maintenance. 
 
Variable Value 
Number of patients receiving maintenance TKI 
therapy 
89 
Number of TKI maintenance therapies, n (%)  
   1 77 (87) 
   >1 12 (13) 
Same TKI given pre-HCT and post-HCT  
         
   No 72 (81) 
   Yes 17 (19) 
TKIs used as maintenance therapies, n  
  Dasatinib  50 
  Imatinib 27 
  Nilotinib 27 
 
Abbreviations 
HCT: hematopoietic cell transplantation; n: number; TKI: tyrosine kinase inhibitor; 
 
 
Table 3. Day 100 landmark multivariate analyses of clinical outcomes.* 
 
 Chronic 
GVHD 
TRM Relapse LFS OS 
Disease status      
   CP1 (reference) -- -- -- -- -- 
   AP -- -- -- 1.3 (0.8-2.0), 
p=0.284 
1.0 (0.6-1.7), 
p=0.901 
   BP -- -- -- 1.8 (1.0-3.1), 
p=0.039 
2.4 (1.3-4.3), 
p=0.005 
   CP2+ -- -- -- 1.7 (1.2-2.4), 
p=0.003 
1.6 (1.1-2.4), 
p=0.013 
Graft Source      
   Bone marrow 
(reference) 
-- -- -- -- -- 
   Cord blood 1.0 (0.6-1.6), 
p=0.848 
2.7 (1.2-5.8) 
p=0.012 
 
-- 
 
-- 
2.6 (1.4-4.7), 
p=0.002 
   Peripheral 
blood 
2.0 (1.4-2.8), 
p<0.001 
2.4 (1.3-4.4), 
p=0.006 
 
-- 
 
-- 
2.1 (1.3-3.4), 
p=0.004 
GVHD 
prophylaxis 
     
   Tacrolimus +/- 
others (reference) 
-- -- -- -- -- 
   Cyclosporine 
+/- others 
0.6 (0.4-0.8), 
p=0.003 
-- -- -- -- 
   Others 0.5 (0.1-2.0), 
p=0.336 
-- -- -- -- 
Age Group      
   18-29 
(reference) 
-- -- -- -- -- 
   30-39 -- -- -- 1.0 (0.6-1.5), 
p=0.849 
-- 
   40-49 -- -- -- 1.2 (0.8-1.9), 
p=0.353 
-- 
   50-59 -- -- -- 1.0 (0.6-1.5), 
p=0.944 
-- 
   ≥60 -- -- -- 2.3 (1.3-3.9), 
p=0.004 
-- 
         
Karnofsky score      
   90-100 
(reference) 
-- -- -- -- -- 
   <90 0.6 (0.4-0.8), 
p<0.001 
-- 2.0 (1.3-3.0), 
p=0.001 
1.4 (1.0-1.9), 
p=0.058 
-- 
Maintenance 
therapy 
     
   No (reference) -- -- -- -- -- 
   Yes 0.8 (0.6-1.1), 
p=0.124 
0.7 (0.4-1.1), 
p=0.130 
1.4 (0.9-2.1), 
p=0.170 
0.9 (0.6-1.2), 
p=0.356 
0.7 (0.5-1.1), 
p=0.078 
 
*Hazard ratios presented with 95% Confidence Interval in parenthesis  
 
Abbreviations 
AP: accelerated phase; BP: blast phase; CP: chronic phase; CR: complete remission; 
GVHD: graft-versus-host disease; LFS: leukemia-free survival; OS: overall survival; 
TRM: transplant-related mortality; 
 
 
 
 
 
         
